Other analysts also recently issued research reports about the company. Citigroup Inc decreased their target price on Vectura Group PLC from GBX 200 ($2.64) to GBX 180 ($2.38) and set a buy rating on the stock in a research note on Monday, September 18th. Shore Capital reissued a buy rating on shares of Vectura Group PLC in a research note on Wednesday, August 16th. J P Morgan Chase & Co reduced their price objective on Vectura Group PLC from GBX 210 ($2.77) to GBX 180 ($2.38) and set an overweight rating on the stock in a research note on Thursday, September 21st. Numis Securities Ltd reaffirmed a buy rating and issued a GBX 205 ($2.71) price objective on shares of Vectura Group PLC in a research note on Thursday, September 7th. Finally, Panmure Gordon reaffirmed a buy rating on shares of Vectura Group PLC in a research note on Wednesday, August 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of GBX 199.63 ($2.63).
Vectura Group PLC (VEC) traded down GBX 1.47 ($0.02) during mid-day trading on Tuesday, hitting GBX 97.03 ($1.28). The stock had a trading volume of 729,537 shares, compared to its average volume of 1,230,000. Vectura Group PLC has a 12-month low of GBX 88.90 ($1.17) and a 12-month high of GBX 166.97 ($2.20).
TRADEMARK VIOLATION WARNING: “Peel Hunt Reaffirms Hold Rating for Vectura Group PLC (VEC)” was originally published by BBNS and is the property of of BBNS. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/peel-hunt-reaffirms-hold-rating-for-vectura-group-plc-vec/1746474.html.
In other news, insider Andrew Derodra acquired 82,000 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were acquired at an average cost of GBX 90 ($1.19) per share, with a total value of £73,800 ($97,387.17). Also, insider Bruno Angelici acquired 70,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was purchased at an average cost of GBX 99 ($1.31) per share, for a total transaction of £69,300 ($91,448.93). Insiders have purchased a total of 152,300 shares of company stock worth $14,339,904 over the last ninety days.
About Vectura Group PLC
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with our FREE daily email newsletter.